A new Egyptian achievement reflects the continent's confidence in regulatory efficiency and enhances Egypt's leading role in unifying African regulatory efforts.
Al-Ghamrawy: The Authority's securing of this continental position serves as an international certificate of confidence in the efficiency of the Egyptian regulatory model and embodies our commitment to supporting African integration in regulatory policies to ensure safe and effective pharmaceutical products for the continent's peoples.
……………………..
In a new strategic achievement that reflects Egypt's prestigious position on the African and international regulatory arena, the Egyptian Drug Authority won the position of Vice-Chairman of the Steering Committee of the Alliance of African Regulatory Authorities classified at Level III (ML3 NRAs) by the World Health Organization. This occurred during the alliance's first meeting, held on July 7th and 8th, 2025, in Abuja, Nigeria.
The victory confirms the confidence of African countries in Egypt's regulatory capabilities and reflects the pivotal role played by the Egyptian Drug Authority in leading joint regulatory work and developing the drug system in Africa.
The Alliance is a pivotal coordinating platform that includes African regulatory bodies that have obtained Maturity Level III classification from the WHO. Its aim is to unify policies and coordinate regulatory efforts to ensure the availability of safe, effective, and high-quality pharmaceutical products across the continent.
During the meeting, Egypt, represented by the Egyptian Drug Authority, was elected to the position of Vice-Chairman of the committee. This confirms the regional confidence in the Authority's efficiency and its ability to advance the unified regulatory work agenda in Africa.
Dr. Ali Al-Ghamrawy, Chairman of the Egyptian Drug Authority, affirmed that this selection is a direct reflection of the Authority's prominent standing at both the African and international levels. This is attributed to its advanced regulatory expertise and an institutional model based on quality and governance, constantly striving to support continental integration in pharmaceutical policies, control, registration, and manufacturing.
He noted that Egypt's attainment of this position aligns with the Authority's vision in enhancing health security within the continent and achieving sustainable development goals through adopting flexible and effective regulatory policies that support an independent African pharmaceutical industry capable of meeting the needs of its populations.
This achievement is a new confirmation of the Egyptian Drug Authority's leadership as one of the pivotal regulatory pillars in the African continent. It has successfully solidified its position as a reference institution relied upon to lead the transformation towards more integrated and effective regulatory systems.
The African side also expressed significant appreciation for the Egyptian Drug Authority's proactive role in supporting coordination and integration efforts among the continent's regulatory bodies. They emphasized that its win of the Vice-Chairman position of the Steering Committee is a culmination of its tangible contributions to promoting the alignment of regulatory policies and developing control and registration mechanisms, thereby establishing the foundations of continental cooperation and enhancing Africa's ability to achieve comprehensive and sustainable pharmaceutical security.
Attendees from the African side included: Dr. Deleese Mimi Darko, Director General of the African Medicines Agency; Dr. Seth Seaneke, Deputy Chief Executive Officer of the Ghana Food and Drug Authority (FDA Ghana); Prof. Dr. Mojisola Christianah Adeyeye, Director General of the National Agency for Food and Drug Administration – Nigeria (NAFDAC); Dr. Boitumelo Semete Makokotlela, CEO of the South African Health Products Regulatory Authority (SAHPRA); Richard Tendai Rukwata, Director General of the Medicines Control Authority of Zimbabwe (MCAZ); Dr. Alioune Abi Talib - Director General of the Senegalese Agency of Pharmaceutical Regulation (ARP); Mr. Abebe Baye, Coordinator of the Local Manufacturing File at the Africa Centers for Disease Control and Prevention; representatives of the Food and Drug Authorities in Rwanda and Tanzania; and the African Medicines Regulatory Harmonization Program.
From the Egyptian Drug Authority, Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman Office, and Dr. Dalia Abu Hussein, General Manager of General Administration of Quality Assurance, participated.
This comes within the framework of the Egyptian Drug Authority's commitment to solidify its regional and international position and enhance its contribution to building an integrated health system across the continent, through adopting best regulatory practices and activating technical cooperation, thereby contributing to achieving sustainable pharmaceutical security for the peoples of Africa.